AbbVie annual shareholders’ equity
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
AbbVie Shareholders’ Equity Growth & History (ABBV)
AbbVie's shareholders’ equity was −$3.27B for fiscal 2025.
View full AbbVie company overviewAbbVie annual shareholders’ equity history
| Fiscal year | Period ended | Shareholders’ equity | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$3.27B | −$6.59B | — |
| 2024 | 2024-12-31 | $3.33B | −$7.04B | −67.91% |
| 2023 | 2023-12-31 | $10.36B | −$6.89B | −39.96% |
| 2022 | 2022-12-31 | $17.25B | $1.85B | +11.98% |
| 2021 | 2021-12-31 | $15.41B | $2.33B | +17.83% |
| 2020 | 2020-12-31 | $13.08B | $21.25B | — |
| 2019 | 2019-12-31 | −$8.17B | $274.0M | — |
| 2018 | 2018-12-31 | −$8.45B | −$13.54B | — |
| 2017 | 2017-12-31 | $5.10B | $461.0M | +9.94% |
| 2016 | 2016-12-31 | $4.64B | $691.0M | +17.52% |
| 2015 | 2015-12-31 | $3.94B | $2.20B | +126.46% |
| 2014 | 2014-12-31 | $1.74B | −$2.75B | −61.22% |
| 2013 | 2013-12-31 | $4.49B | $4.84B | — |
| 2012 | 2012-12-31 | −$350.0M | — | — |
AbbVie quarterly shareholders’ equity
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shareholders’ equity | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$5.93B | −$5.75B | — |
| Q1 2026 | 2026-03-31 | −$6.66B | −$8.08B | — |
| Q4 2025 | 2025-12-31 | −$3.27B | −$6.59B | — |
| Q3 2025 | 2025-09-30 | −$2.64B | −$8.67B | — |
| Q2 2025 | 2025-06-30 | −$183.0M | −$6.96B | — |
| Q1 2025 | 2025-03-31 | $1.42B | −$6.59B | −82.27% |
| Q4 2024 | 2024-12-31 | $3.33B | −$7.04B | −67.91% |
| Q3 2024 | 2024-09-30 | $6.03B | −$6.06B | −50.12% |
| Q2 2024 | 2024-06-30 | $6.78B | −$6.09B | −47.32% |
| Q1 2024 | 2024-03-31 | $8.01B | −$5.27B | −39.68% |
| Q4 2023 | 2023-12-31 | $10.36B | −$6.89B | −39.96% |
| Q3 2023 | 2023-09-30 | $12.09B | −$3.90B | −24.38% |
| Q2 2023 | 2023-06-30 | $12.87B | −$1.79B | −12.20% |
| Q1 2023 | 2023-03-31 | $13.27B | −$3.01B | −18.48% |
| Q4 2022 | 2022-12-31 | $17.25B | $1.85B | +11.98% |
| Q3 2022 | 2022-09-30 | $15.99B | $2.44B | +18.04% |
| Q2 2022 | 2022-06-30 | $14.65B | $2.08B | +16.58% |
| Q1 2022 | 2022-03-31 | $16.28B | $2.57B | +18.77% |
| Q4 2021 | 2021-12-31 | $15.41B | $2.33B | +17.83% |
| Q3 2021 | 2021-09-30 | $13.55B | −$1.72B | −11.26% |
| Q2 2021 | 2021-06-30 | $12.57B | −$2.14B | −14.54% |
| Q1 2021 | 2021-03-31 | $13.71B | $21.13B | — |
| Q4 2020 | 2020-12-31 | $13.08B | $21.25B | — |
| Q3 2020 | 2020-09-30 | $15.27B | $23.50B | — |
| Q2 2020 | 2020-06-30 | $14.71B | $23.27B | — |
| Q1 2020 | 2020-03-31 | −$7.42B | $411.0M | — |
| Q4 2019 | 2019-12-31 | −$8.17B | $274.0M | — |
| Q3 2019 | 2019-09-30 | −$8.23B | −$5.30B | — |
| Q2 2019 | 2019-06-30 | −$8.57B | −$5.19B | — |
| Q1 2019 | 2019-03-31 | −$7.83B | −$11.38B | — |
| Q4 2018 | 2018-12-31 | −$8.45B | −$13.54B | — |
| Q3 2018 · Sep 30 | 2018-09-30 | −$2.92B | −$9.61B | — |
| Q2 2018 | 2018-06-30 | −$3.38B | −$9.38B | — |
| Q1 2018 | 2018-03-31 | $3.55B | −$1.45B | −28.91% |
| Q4 2017 | 2017-12-31 | $5.10B | $461.0M | +9.94% |
| Q3 2017 | 2017-09-30 | $6.69B | $218.0M | +3.37% |
| Q2 2017 | 2017-06-30 | $6.01B | $369.0M | +6.54% |
| Q1 2017 | 2017-03-31 | $5.00B | $355.0M | +7.65% |
| Q4 2016 | 2016-12-31 | $4.64B | $691.0M | +17.52% |
| Q3 2016 | 2016-09-30 | $6.47B | $1.61B | +33.02% |
| Q2 2016 | 2016-06-30 | $5.64B | $136.0M | +2.47% |
| Q1 2016 | 2016-03-31 | $4.64B | $3.27B | +237.18% |
| Q4 2015 | 2015-12-31 | $3.94B | $2.20B | +126.46% |
| Q3 2015 | 2015-09-30 | $4.86B | $218.0M | +4.69% |
| Q2 2015 | 2015-06-30 | $5.50B | $286.0M | +5.48% |
| Q1 2015 | 2015-03-31 | $1.38B | −$3.32B | −70.68% |
| Q4 2014 | 2014-12-31 | $1.74B | −$2.75B | −61.22% |
| Q3 2014 | 2014-09-30 | $4.64B | $1.07B | +29.86% |
| Q2 2014 | 2014-06-30 | $5.22B | $1.66B | +46.66% |
| Q1 2014 | 2014-03-31 | $4.70B | $1.74B | +58.84% |
| Q4 2013 | 2013-12-31 | $4.49B | $4.84B | — |
| Q3 2013 | 2013-09-30 | $3.58B | — | — |
| Q2 2013 | 2013-06-30 | $3.56B | — | — |
| Q1 2013 | 2013-03-31 | $2.96B | — | — |
| Q4 2012 | 2012-12-31 | −$350.0M | — | — |
AbbVie shareholders’ equity trends
Over the last five fiscal years, AbbVie's shareholders’ equity decreased from $13.08B to −$3.27B, a change of −$16.35B. The latest reported quarter, Q2 2026, shows −$5.93B.
About the metric
What shareholders’ equity means
Shareholders’ equity is the residual accounting value attributable to shareholders after liabilities are subtracted from assets. It can change through earnings, losses, dividends, share issuance, repurchases, and other comprehensive income.
Calculation and source
SEC-reported shareholders’ equity
TickerStat standardizes stockholders’ or shareholders’ equity reported in company SEC filings at each balance-sheet date. Negative equity is retained because it can be economically meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review AbbVie source filings ↗Community posts
FDA clears at-home Skyrizi induction for Crohn’s disease
AbbVie ($ABBV) received FDA approval for subcutaneous induction dosing of Skyrizi in adults with moderately to severely active Crohn’s disease. Patients can now begin treatment at home using an on-body injector, extending that delivery opti ...
AbbVie meets pivotal hidradenitis endpoint with lutikizumab
AbbVie ($ABBV) reported that lutikizumab met the main endpoint and all eight ranked secondary endpoints in the Phase 3 INTREPID trial for moderate to severe hidradenitis suppurativa. At week 16, 31.4% of treated patients achieved HiSCR75, c ...
AbbVie’s menstrual-migraine study meets its primary and all ranked secondary goals
AbbVie ($ABBV) reported positive Phase 3 LUNA results for atogepant in menstrual migraine. The study enrolled 468 women and evaluated treatment across three menstrual cycles. Migraine days during the assessed menstrual period fell by 1.20 d ...
